2:24 PM
 | 
Jun 13, 2018
 |  BC Extra  |  Clinical News

Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) plummeted $3.14 (75%) to $1.04 on Wednesday when the company said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch beyond the biotech's current means. Flex said it will evaluate strategic alternatives, including a sale.

Flex found that a subset of...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >